• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立体外-体内关联的溶解和转化建模策略——研讨会总结报告

Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.

机构信息

Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

AAPS J. 2019 Feb 11;21(2):29. doi: 10.1208/s12248-019-0298-x.

DOI:10.1208/s12248-019-0298-x
PMID:30746576
Abstract

This publication summarizes the proceedings of day 2 of a 3-day workshop on "Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development." Patient-centric drug product development from a drug product quality perspective necessitates the establishment of clinically relevant drug product specifications via an in vitro-in vivo link. Modeling and simulation offer a path to establish this link; in this regard, physiologically based modeling has been implemented successfully to support regulatory decision-making and drug product labeling. In this manuscript, case studies of physiologically based biopharmaceutics modeling (PBBM) applied to drug product quality are presented and summarized. These case studies exemplify a possible path to achieve an in vitro-in vivo link and encompass (a) development of biopredictive dissolution methods to support biowaivers, (b) model-informed formulation selection, (c) predicting clinical formulation performance, and (d) defining a safe space for regulatory flexibility via virtual bioequivalence (BE). Workflows for the development and verification of absorption models/PBBM and for the establishment of a safe space using dissolution as an input are described with examples. Breakout session discussions on topics, such as current challenges and some best practices in model development and verification, are included as part of the Supplementary material.

摘要

本出版物总结了为期三天的“溶解和转化建模策略促进以患者为中心的产品开发”研讨会的第二天的会议记录。从药物产品质量的角度来看,以患者为中心的药物产品开发需要通过体内外关联来建立临床相关的药物产品规格。建模和模拟为建立这种联系提供了一种途径;在这方面,基于生理学的建模已成功用于支持监管决策和药物产品标签。在本文中,介绍并总结了应用于药物产品质量的基于生理学的生物药剂学建模 (PBBM) 的案例研究。这些案例研究举例说明了实现体内外关联的可能途径,包括:(a) 开发生物预测性溶出方法以支持生物豁免,(b) 基于模型的配方选择,(c) 预测临床配方性能,以及 (d) 通过虚拟生物等效性 (BE) 定义监管灵活性的安全空间。描述了吸收模型/PBBM 的开发和验证以及使用溶出度作为输入建立安全空间的工作流程,并附有示例。关于模型开发和验证方面的当前挑战和一些最佳实践等主题的分组讨论作为补充材料的一部分包含在内。

相似文献

1
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.建立体外-体内关联的溶解和转化建模策略——研讨会总结报告
AAPS J. 2019 Feb 11;21(2):29. doi: 10.1208/s12248-019-0298-x.
2
Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.生理药代动力学建模(PBBM)在支持药物产品质量中的应用:研讨会总结报告。
J Pharm Sci. 2021 Feb;110(2):594-609. doi: 10.1016/j.xphs.2020.10.059. Epub 2020 Nov 3.
3
Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.生理相关生物药剂学建模的开发与验证最佳实践。研讨会总结报告
J Pharm Sci. 2021 Feb;110(2):584-593. doi: 10.1016/j.xphs.2020.09.058. Epub 2020 Oct 13.
4
PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.基于生理的药代动力学吸收模型:建立体外-体内关联-行业视角。
AAPS J. 2019 Jan 23;21(2):19. doi: 10.1208/s12248-019-0292-3.
5
Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.生物药剂学中基于生理的药代动力学建模:创新药和仿制药生物等效性安全空间确立的案例研究
Pharm Res. 2023 Feb;40(2):337-357. doi: 10.1007/s11095-022-03319-6. Epub 2022 Jul 15.
6
Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.利用生理相关药代动力学建模(PBBM)确定即释口服剂型的生物等效性安全范围:案例研究。
J Pharm Sci. 2021 Dec;110(12):3896-3906. doi: 10.1016/j.xphs.2021.09.017. Epub 2021 Sep 20.
7
In Vitro Biopredictive Methods: A Workshop Summary Report.体外生物预测方法:研讨会总结报告。
J Pharm Sci. 2021 Feb;110(2):567-583. doi: 10.1016/j.xphs.2020.09.021. Epub 2020 Sep 19.
8
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.基于生理学的生物药剂学建模 (PBBM):药品质量、监管和行业视角的最佳实践:2023 年研讨会总结报告。
Mol Pharm. 2024 May 6;21(5):2065-2080. doi: 10.1021/acs.molpharmaceut.4c00202. Epub 2024 Apr 10.
9
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.利用体外生物相关溶解试验和基于生理的群体药代动力学建模建立虚拟生物等效性和临床相关规格。案例示例:萘普生。
Eur J Pharm Sci. 2020 Feb 15;143:105170. doi: 10.1016/j.ejps.2019.105170. Epub 2019 Nov 27.
10
Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.当前转化模型策略的状态和未来展望,以支持药物产品开发、制造变更和控制:研讨会总结报告。
J Pharm Sci. 2021 Feb;110(2):555-566. doi: 10.1016/j.xphs.2020.04.021. Epub 2020 May 4.

引用本文的文献

1
Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions.基于生理学的生物药剂学模型报告模板的开发:鉴于监管提交要求,对提高质量的考量
Mol Pharm. 2025 Jun 2;22(6):2735-2746. doi: 10.1021/acs.molpharmaceut.5c00225. Epub 2025 Apr 29.
2
Physiologically-Based Biopharmaceutics Modeling for Ibuprofen: Identifying Key Formulation Parameter and Virtual Bioequivalence Assessment.基于生理学的布洛芬生物药剂学建模:确定关键制剂参数及虚拟生物等效性评估
Pharmaceutics. 2025 Mar 24;17(4):408. doi: 10.3390/pharmaceutics17040408.
3
In Vitro-In Silico Approach in the Development of Clopidogrel Solid Dispersion Formulations.

本文引用的文献

1
Dissolution Testing in Drug Product Development: Workshop Summary Report.药物产品开发中的溶出度测试:研讨会总结报告。
AAPS J. 2019 Jan 28;21(2):21. doi: 10.1208/s12248-018-0288-4.
2
Maximizing the Role of Physiologically Based Oral Absorption Modeling in Generic Drug Development.最大化基于生理学的口服吸收模型在仿制药开发中的作用。
Clin Pharmacol Ther. 2019 Feb;105(2):307-309. doi: 10.1002/cpt.1242. Epub 2018 Nov 20.
3
Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report.临床相关溶出度测试的应用:研讨会总结报告。
氯吡格雷固体分散体剂型开发中的体外-计算机模拟方法
Bioengineering (Basel). 2025 Mar 30;12(4):357. doi: 10.3390/bioengineering12040357.
4
Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report.基于生理的生物药剂学建模(PBBM)应用的现状与新视野:研讨会报告
Mol Pharm. 2025 Jan 6;22(1):5-27. doi: 10.1021/acs.molpharmaceut.4c01148. Epub 2024 Dec 16.
5
Advancing Virtual Bioequivalence for Orally Administered Drug Products: Methodology, Real-World Applications and Future Outlook.推进口服药品的虚拟生物等效性:方法、实际应用及未来展望
Pharmaceuticals (Basel). 2024 Jul 3;17(7):876. doi: 10.3390/ph17070876.
6
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.生理药代动力学模型参数化:研讨会总结报告。
Mol Pharm. 2024 Aug 5;21(8):3697-3731. doi: 10.1021/acs.molpharmaceut.4c00526. Epub 2024 Jun 30.
7
Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.基于生理的生物药剂学模型用于 Gefapixant IR 制剂的开发和定义生物等效性溶出安全范围。
AAPS J. 2024 Jun 11;26(4):69. doi: 10.1208/s12248-024-00938-2.
8
Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations.常规与基于机制的 IVIVC:建立缓释制剂溶出度安全范围的比较研究。
AAPS PharmSciTech. 2024 May 28;25(5):118. doi: 10.1208/s12249-024-02819-5.
9
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.基于生理学的生物药剂学建模 (PBBM):药品质量、监管和行业视角的最佳实践:2023 年研讨会总结报告。
Mol Pharm. 2024 May 6;21(5):2065-2080. doi: 10.1021/acs.molpharmaceut.4c00202. Epub 2024 Apr 10.
10
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software.基于 GastroPlus™ 软件的阿托伐他汀片剂生物等效性的计算机预测。
BMC Pharmacol Toxicol. 2023 Nov 28;24(1):69. doi: 10.1186/s40360-023-00689-4.
AAPS J. 2018 Aug 27;20(6):93. doi: 10.1208/s12248-018-0252-3.
4
Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.促进以患者为中心的药物产品开发的溶解和转化建模策略:M-CERSI 研讨会总结报告。
AAPS J. 2018 Apr 9;20(3):60. doi: 10.1208/s12248-018-0213-x.
5
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.基于生理学的药物代谢动力学模型预测 Panobinostat(LBH589)作为药物相互作用的受害者和肇事者。
Drug Metab Dispos. 2017 Dec;45(12):1304-1316. doi: 10.1124/dmd.117.076851. Epub 2017 Sep 14.
6
Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.通过吸收建模和溶出度测试对难溶性化合物巴斯米尼尔速释制剂的药物释放特性进行表征。
AAPS J. 2017 May;19(3):827-836. doi: 10.1208/s12248-017-0060-1. Epub 2017 Feb 24.
7
Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.开发一种新型简化的生理药代动力学吸收模型以解释奥昔布宁OROS®制剂更高的相对生物利用度。
AAPS J. 2016 Nov;18(6):1532-1549. doi: 10.1208/s12248-016-9965-3. Epub 2016 Sep 8.
8
Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications.在新药申请中的体内体外相关性 (IVIVC) 的监管经验。
AAPS J. 2016 Nov;18(6):1379-1390. doi: 10.1208/s12248-016-9966-2. Epub 2016 Aug 1.
9
Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets.基于来苏地尔速释片吸收的PBPK模型对药品溶出速率和原料药粒度规格的论证
Mol Pharm. 2016 Sep 6;13(9):3256-69. doi: 10.1021/acs.molpharmaceut.6b00497. Epub 2016 Jul 27.
10
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.模型引导的药物发现与开发中的良好实践:实践、应用与文档记录
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.